AtriCure — Third Quarter 2026 Earnings Summary

AtriCure reported third-quarter 2026 worldwide revenue of $154.5 million, representing a 15.0% year-over-year increase driven by growth in U.S. sales of cryoSPHERE MAX probes, EnCompass clamps, and AtriClip devices. The company achieved profitability expansion with net income of $4.1 million and adjusted EBITDA of $26.8 million, while gross margin improved to 77.3%. For the full year 2026, management projects revenue between $606 million and $610 million and adjusted EBITDA between $91 million and $94 million. Additionally, the company expects full-year net income per share to range from $0.21 to $0.27 and adjusted earnings per share to be approximately $0.40 to $0.46.